Contractor
BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
ALLSCHWIL
- UEI
- UA43HWRNXFS3
- Resolved by
- uei
- Confidence
- 1.000
Obligated to date
$276,138,5411
Awards
3
Agencies served
1
Active from Apr 19, 2016 to Oct 7, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 75A50123C00050 VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | Department of Health and Human Services | PA | Sep 15, 2023 | $45,192,122 |
| HHSO100201600002C IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | Department of Health and Human Services | — | Apr 19, 2016 | $108,445,187 |
| 75A50124C00033 THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | Department of Health and Human Services | — | Sep 18, 2024 | $122,501,232 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier UA43HWRNXFS3, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Oct 21, 2026.